Ping H. Wang, M.D.

949-763-2204
Ping H. Wang, M.D.
Endocrinologist
Clinical Expertise
  • Bone Health
  • Cancer Related Endocrinopathies
  • Diabetes
  • Endocrine Tumors
  • Endocrinology
  • Thyroid Tumors
Research Area
  • Diabetes & Metabolism
Other Languages Spoken
Mandarin
Academic Appointments
  • Professor and Chair, Department of Diabetes, Endocrinology & Metabolism
Clinical Teams
Diabetes, Endocrinology & Metabolism
Endocrinology and Metabolism Treatments
Pituitary Disorders and Tumors
Research Teams
Diabetes, Endocrinology & Metabolism
Ping H. Wang, M.D., brings three decades of distinguished expertise in diabetes research and treatment to City of Hope. As we expand our work in Southern California, Dr. Wang will continue to grow our diabetes program and support our commitment to cure all forms of diabetes, including type 1.
 
Dr. Wang earned his medical degree at Taiwan’s Kaohsiung Medical College and an advanced degree in epidemiology at Harvard, where he also completed fellowships in endocrinology and metabolism.
 
He joined University of California Irvine’s Department of Medicine in 1994. He was the founding director for the school's diabetes center, and served as chief of endocrinology for the past decade.
 
Dr. Wang is passionate about diabetes because of its urgency. “There is a worldwide diabetes epidemic,” he says, “with more than 400 million people affected. Diabetes has become the 21st century's major public health concern and will continue to swell if we don’t find a cure.”
 
Recipient of multiple “Top Doctor” awards, the bilingual (English, Mandarin) Dr. Wang is excited to join City of Hope. He hopes “to help create a center of excellence for diabetes and endocrine tumors through clinical care, research and education."

Location

Education & Experience

Board Certifications

  • 2009, American Board of Endocrinology, Diabetes, and Metabolism

  • 2002, American Board of Internal Medicine

Degrees

  • 1984, M.D., Kaohsiung Medical College, Kaohsiung, Taiwan

  • 1985, S.M., Epidemiology, Harvard School of Public Health, Boston, MA

Fellowship

  • 1991-1994, Endocrinology and Metabolism, Joslin Diabetes Center, and Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA

  • 1985-1988, Joslin Diabetes Center, Section on Metabolism, Harvard Medical School, Boston, MA

Residency

  • 1988-1991, Department of Medicine, Boston VA Medical Center and Tufts University School of Medicine, Boston, MA

Internship

  • 1988-1991, Department of Medicine, Boston VA Medical Center and Tufts University School of Medicine, Boston, MA

Professional Experience

  • 2020-present, Chair, Department of Diabetes, Endocrinology & Metabolism, City of Hope, Duarte, CA

  • 2011-2020, Director, UC Irvine Health Diabetes Center, Irvine, CA

  • 2006-2020, Professor with Tenure, Department of Medicine, Department of Physiology and Biophysics, University of California Irvine, Irvine, CA

  • 2005-2020, Director, UC Irvine Center for Diabetes Research and Treatment, Irvine, CA

  • 2003-2020, Chief, Division of Endocrinology, Diabetes, and Metabolism, UC Irvine, Irvine, CA

  • 2004-2011, Director, Joslin Diabetes Center at UC Irvine, Irvine, CA

  • 2000-2006, Associate Professor with Tenure, Department of Medicine, Department of Biological Chemistry, Department of Physiology and Biophysics, University of California Irvine, Irvine, CA

  • 2002-2005, Director, Center for Cardiovascular Hormone Research, UC Irvine, Irvine, CA

  • 2001-2002, Acting Chief, Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, University of California Irvine, Irvine, CA

  • 1994-2000, Assistant Professor, Department of Biological Chemistry
    University of California Irvine, Irvine, CA

  • 1994-2000, Assistant Professor, Department of Medicine, Division of Endocrinology, Diabetes, and Metabolism, University of California Irvine, Irvine, CA

Awards & Memberships

Awards

  • 2015-2020, Top Doctors, Orange Coast Magazine

  • 2015-2020, Super Doctors, LA Magazine

  • 2007-2020, Best Doctors in America, BestDoctors Inc.

  • 2002-2020, America’s Top Doctors, Castle Connolly Medical LTD, NY

  • 1993, Juvenile Diabetes Foundation Research Fellowship Award

  • 1987, Juvenile Diabetes Foundation Research Fellowship Award

  • 1984, Best Intern Award, Kaohsiung Medical College

Memberships

  • American Medical Association, Endocrine Society

  • American Federation of Clinical Research

  • American Diabetes Association, American Heart Association
    1995-2020, Chao Family Comprehensive Cancer Center University of California

Publications

  • Chen Y-H, Su C-C, Wu D, Lock LF, Donovan PJ, Kayala MA, Baldi P, Lee HC, Chen Y, Wang PH. Mitochondrial Akt Signaling Modulated Reprogramming of Somatic Cells. Scientific Reports, 2019 9(1):9919.
  • Kedaigle AJ, Fraenkel E, Atwal RS, Wu M, Gusella JF, MacDonald ME, Kaye JA, Finkbeiner S, Mattis VB, Tom CM, Svendsen C, King AR, Chen Y, Stocksdale JT, Lim, RG, Casale M, Wang PH, Thompson LM, Akimov SS, Ratovitski T, Arbez N, Ross CA. Bioenergetic deficits in Huntington's disease iPSC-derived neural cells and rescue with glycolytic metabolites. Hum Mol Genet. 2019 Feb 15. pii: ddy430.
  • Chalkia D, Chang Y-C, Derbeneva O, Lvova, M, Wang PH, Mishmar D, LiuX, Singh L, Chuang L-M, Wallac DC. Mitochondrial DNA Associations with East Asian Metabolic Syndrome. BBA-Bioenergetics, 2018; 1859;878-892.
  • Zhou Y, Chen Y , Hu Y, Yu L, Tran K, Giedzinski E, Ru N, Gau A, Pan F, Qiao J, Atkin N, Ly K, Lee N, Siegel E, Linskey M, Wang P, Limoli C. The role of EGFR double minutes in modulating the response of malignant gliomas to radiotherapy. Oncotarget 2017; 8:80853-68.
  • Fan W, Lee D, Choi S, Billimek J, Wang PH. The Changing Landscape of Diabetes Prevalence among First-Generation Asian Immigrants in California from 2003 to 2013. BMJ Open Diabetes Research and Care 2017; 5:e000327.
  • Pedersen BA, Wang W, Taylor JF, Khattab O, Chen Y-H, Edwards RA, Yazdi, P, Wang PH. Hepatic proteomic analysis revealed altered metabolic pathways in insulin resistant Akt1+/-/Akt2-/- mice. Metabolism 2015; 64(12):1694-1703.
  • Pedersen BA, Wang W, Yazdi A, Taylor JF, Khattab O, Chen Y-H, Chen Y, Wang PH. Novel remodeling of the mouse heart mitochondrial proteome in response to acute insulin stimulation. Nutr Metab Cardiovasc Dis. 2015; 25(12):1152-8.
  • Chen Y, Chernyavsky A, Weber R, Grando SA, Wang PH. Critical role of FcRn in the pathogenic action of anti-mitochondrial autoantibodies synergizing with anti-desmoglein autoantibodies in pemphigus vulgaris. J Biol Chem. 2015; 290:23826-37.
  • Ke C, Ru N, Chen Y, Yu L, Siegel ER, Linskey ME, Wang PH, Xing J, Zhou YH. Cell context-dependent dual effects of EFEMP1 stabilizes subpopulation equilibrium in responding to changes of in vivo growth environment. Oncotarget 2015; 6(31):30762-72.
  • Yazdi A, Pedersen BA, Taylor JF, Khattab O, Chen Y-H, Chen Y, Jacobsen SE, Wang PH. Increasing nucleosome occupancy is correlated with an increasing mutation rate so long as DNA repair machinery is intact. PLoS One 2015; 10(8):e0136574.
  • Yazdi A, Pedersen BA, Taylor JF, Khattab O, Chen Y-H, Chen Y, Jacobsen SE, Wang PH. Nucleosome organization in human embryonic stem cells. PLoS One 2015; 10 (8): e0136314.
  • Chernyavsky A, Chen Y, Wang PH, Grando SA. Pemphigus vulgaris antibodies target the mitochondrial nicotinic acetylcholine receptors that protect keratinocytes from apoptolysis. Int Immunopharmacol. 2015; 29(1): 76-80.
  • Ke C, Tran K, Chen Y, Di Donato AT, Yu L, Hu Y, Linskey ME, Wang PH, Limoli C, Zhou YH. Linking differential radiation responses to glioma heterogeneity. Oncotarget. 2014; 5(6): 1657–1665.
  • Deng W, Leu HB, Chen Y, Chen YH, Epperson CM, Juang C, Wang PH. Protein Kinase B (PKB/Akt1) Formed Signaling Complexes with Mitochondrial Proteins and Protected against Glycolytic Energy Impairment in Stressed Cardiomyocytes. Endocrinology. 2014; 155(5):1618-28.
  • Yazdi PG, Moradi H, Yang JY, Wang PH, Vaziri ND. Skeletal muscle mitochondrial depletion and dysfunction in chronic kidney disease. Int J Clin Exp Med. 2013; 6(7):532-9.
  • Upadhyay S, Eckel-Mahan K, Mirbolooki M, Tjong I, Griffey S, Schmunk G, Koehne A, Halbout B, Iadonato S, Pedersen B, Borrelli E, Wang PH, Mukherjee J, Sassone-Corsi P, Chandy KG. Selective Kv1.3 channel blocker as therapeutic for obesity and insulin resistance. Proc Natl Acad Sci USA. 2013; 110(24):E2239-48.

Ratings & Reviews

Ratings and reviews below are gathered from the Press Ganey Clinician and Group Consumer Assessment of Healthcare Providers and Systems (CG CAHPS) survey. CG CAHPS is a standardized survey that is used to measure a patient's experience in the physician office setting. Ratings are an average of all responses to questions about a provider's care, with five stars being the highest.